Entries |
Document | Title | Date |
20080199490 | Immunogenic Composition - The present application discloses an immunogenic composition comprising a Hib saccharide conjugate and at least two further bacterial saccharide conjugates wherein the Hib conjugate is present in a lower saccharide dose than the mean saccharide dose of all the at least two further bacterial saccharide conjugates. | 08-21-2008 |
20080206276 | Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections - Immunogenic compositions and methods for eliciting an immune response against | 08-28-2008 |
20080248059 | Dimensional Analysis of Saccharide Conjugates with Gpc & Sec-Mals - GPC (gel permeation chromatography) and size exclusion chromatography with detection by multi-angle light scattering photometry (SEC-MALS) can be used to accurately measure molecular size and molar mass, respectively, of saccharide conjugates. The invention provides (a) a process for measuring the molecular size of a conjugated saccharide antigen within a sample, comprising a step of analyzing the sample by GPC, and (b) a process for measuring the molar mass of a conjugated saccharide antigen within a sample, comprising a step of analysing the sample by SEC-MALS. | 10-09-2008 |
20080254057 | Combined Meningococcal Conjugates With Common Carrier Protein - Carrier-induced epitopic suppression is of particular concern where multiple conjugates with the same carrier protein are administered simultaneously. To avoid the suppression, the invention minimises the amount of unconjugated carrier protein in a vaccine. The invention provides a composition for immunising a patient against a disease caused by | 10-16-2008 |
20080254058 | Pharmaceutical Composition Comprising a Bacterial Cell Displaying a Heterologous Proteinaceous Compound - The present invention pertains to a composition for the manufacture of a medicament comprising living or dead bacteria with controlled amounts of surface-coupled proteins or proteinaceous compounds and a method for the preparation of the composition. The bacterium provides a multivalent heterologous protein display vehicle that may be used in the manufacture of vaccines or medicaments for delivery via the mucosa. | 10-16-2008 |
20080274135 | Measuring Degree of Polymerisation for Meningococcal Capsular Saccharides That Contain Sialic Acid - The degree of polymerisation (DP) is an important parameter for analysis of saccharide antigens, particularly in glycoconjugates. The invention provides methods that can be used to measure DP for capsular saccharides, particularly for meningococcal saccharides e.g. from serogroups W135 and Y. A preferred method is based on reduction of terminal sialic acid residues on saccharides, with DP then being calculated by comparing the molar ratio of total sialic acid to reduced sialic acid. | 11-06-2008 |
20080286300 | Analysis of Saccharide Vaccines Without Interference - The invention is based on methods that allow analysis of mixed meningococcal saccharides from multiple serogroups even though they share monosaccharide units. With a combination of saccharides from serogroups C, W135 and Y, the invention analyses sialic acid, glucose and galactose content. The glucose and galactose results are used to directly quantify saccharides from serogroups Y and W135, respectively, and the combined glucose and galactose content is subtracted from the sialic acid content to quantify saccharides from serogroup C. The three serogroups can thus be resolved even though their monosaccharide contents overlap. The three different monosaccharide analyses can be performed on the same material, without interference between the monosaccharides and without interference from any other saccharide materials in the composition (e.g. lyophilisation stabilisers). The method can be used to analyse total and free saccharide in conjugate vaccines and simplifies quality control of vaccines containing capsular saccharides from multiple serogroups. | 11-20-2008 |
20080317775 | Bacterial Antigens and Uses Thereof - Novel enzymes, processes and antigenic structures useful in producing vaccines and compounds useful in combating gram-negative bacteria are described. Enzymes were isolated from the slime mould | 12-25-2008 |
20090010959 | Pneumococcal Polysaccharide Conjugate Vaccine - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent | 01-08-2009 |
20090017059 | Vaccine Comprising Streptococcus Pneumoniae Capsular Polysaccharide Conjugates - The present invention discloses an immunogenic composition comprising | 01-15-2009 |
20090017060 | Cleavable Vaccine Compositions and Uses Thereof and Methods of Making and Using the Same - The invention relates to methods for making vaccines using linkages that are cleavable under lysosomal processing conditions, and vaccine compositions obtained therefrom. In some embodiments, the vaccines comprise a tumor antigen, an immunogenic carrier and a linker covalently linking the tumor antigen and the immunogenic carrier by a thio ether linkage. Vaccines of preferred embodiments can be used against a cellular proliferative disease that is characterized by the tumor antigen. | 01-15-2009 |
20090041802 | IMMUNOGENIC COMPOSITION - The present application discloses an immunogenic composition comprising | 02-12-2009 |
20090060945 | Integration of meningococcal conjugate vaccination - Conjugated meningococcal capsular saccharides will be introduced into immunisation schedules in the near future, but the phenomenon of “carrier suppression” must first be addressed, particularly where multiple conjugates are to be used. It has been found that diphtheria toxoid and its derivatives (such as CRM197) can safely be used as the carrier protein, even where multiple meningococcal conjugates are administered at the same time and where a patient has previously been exposed to the carrier protein, either in the form of a previous immunogen (e.g. in a DTP vaccine) or as a previous carrier protein (e.g. in a Hib or pneumococcal conjugate vaccine). The invention provides a method for immunising a patient, comprising administering multiple conjugates of meningococcal capsular saccharides, wherein each conjugate comprises a diphtheria toxoid (or derivative thereof) carrier protein, and the capsular saccharide, and wherein the patient has been pre-immunised with a diphtheria toxoid (or derivative thereof). | 03-05-2009 |
20090098156 | Regimens for immunisation with meningococcal conjugates - Multivalent meningococcal conjugate vaccines are administered according to a schedule in which at least one or two doses are administered to a patient aged between 0 and 12 months, and a further dose is administered to a patient aged between 12 and 24 months. | 04-16-2009 |
20090117147 | VACCINES COMPRISING OUTER MEMBRANE VESICLES FROM GRAM NEGATIVE BACTERIA - The present invention relates to the field of vaccine formulation, particularly the field of novel adjuvant compositions comprising outer membrane vesicles (or blebs), and advantageous methods of detoxifying these compositions, and advantageous methods of use of such adjuvants. | 05-07-2009 |
20090117148 | Capsular Polysaccharides Solubilisation and Combination Vaccines - Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1. | 05-07-2009 |
20090130140 | Capsular Polysaccharide Solubilisation and Combination Vaccines - Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1. | 05-21-2009 |
20090136541 | IMMUNOGENIC COMPOSITION - The present application discloses an immunogenic composition comprising at least 2 different | 05-28-2009 |
20090162394 | VACCINE - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent | 06-25-2009 |
20090181048 | CANCER DRUG DELIVERY USING MODIFIED TRANSFERRIN - The present invention provides transferrin (Tf) conjugates of anti-cancer agents with increased cellular association and increased cellular internalization. The present invention also provides methods of treating cancer comprising administration of a Tf conjugate with increased cellular association to a subject with cancer. The present invention additionally provides methods of making, as well as screening for, Tf conjugates with increased cellular association or cellular internalization. The present invention also provides Tf conjugates with increased cellular association and internalization for delivering nucleic acids to cancer cells. | 07-16-2009 |
20090181049 | Capsular polysaccharide solubilisation and combination vaccines - Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1. | 07-16-2009 |
20090196886 | VACCINE AGAINST NICOTINE ADDICTION - The present invention provides a hapten in the form of a novel nicotine derivative that may suitably be conjugated with an appropriate carrier to yield an effective vaccine against nicotine addiction. More particularly, the invention relates to a nicotine derivative of the following formula (I): | 08-06-2009 |
20090252759 | IMMUNOGENIC COMPOSITION - The present application relates to an immunogenic composition comprising at least 2 conjugates of | 10-08-2009 |
20090269370 | VACCINES COMPRISING MULTIMERIC HSP60 PEPTIDE CARRIERS - The present invention provides improved vaccine compositions having enhanced immunogenicity and methods of using same. The compositions and methods include immunogenic conjugates containing peptide carriers derived from heat shock protein 60 (HSP60). The known synthetic peptide carrier, p458, provides significantly improved immunogenicity when provided as a multimeric conjugate comprising a plurality of peptide carrier units conjugated to each antigen. Cell vaccine compositions comprising antigen presenting cells loaded with multimeric p458 conjugates are also provided. | 10-29-2009 |
20090297553 | Regimens for Immunisation With Meningococcal Conjugates - Multivalent meningococcal conjugate vaccines are administered according to a schedule in which a first dose is administered to a patient aged between 0 and 12 months, and a second dose is administered to the patient aged between 12 and 24 months. | 12-03-2009 |
20090304734 | IMMUNOGENS FOR MENINGITIDIS-A VACCINES - An oligosaccharide useful for a Meningitidis A vaccine contains a first mannose unit having a spacer in the alpha configuration at C-1, which spacer is capable of conjugating to a protein, and which is connected to a second mannose unit through a 1,6-linkage which connects C-6 of the first unit to C-1 of the second unit, wherein the 1,6-linkage comprises a phosphonate. Related methods of making such compounds, analogous compounds, or intermediates thereof are also disclosed. | 12-10-2009 |
20100003276 | Methods for treating anthrax and inhibiting lethal factor - This invention relates to a method of inhibiting lethal factor (LF) or for treating anthrax and other conditions related to anthrax infection comprising co-administration of an effective amount of an LF inhibitor and a vaccine to a patient in need of such treatment. Such co-administration unexpectedly provides an effective immune response. | 01-07-2010 |
20100015175 | Vaccine - The invention relates to a vaccine for the treatment of disease caused by | 01-21-2010 |
20100040647 | VACCINE - The present invention relates to the field of vaccines for protecting against polio, and in particular to combination vaccines for protecting against polio, diphtheria, tetanus, and pertussis diseases. Specifically, vaccines comprising reduced dose inactivated poliovirus are provided | 02-18-2010 |
20100092509 | Hypo- and Hyper- Acetylated Meningococcal Capsular Saccharides - Capsular saccharides derived from serogroups W135 and Y of | 04-15-2010 |
20100104593 | MENINGOCOCCAL CONJUGATE VACCINATION - Conjugated meningococcal capsular saccharides will be introduced into immunisation schedules in the near future, but the phenomenon of “carrier suppression” must first be addressed, particularly where multiple conjugates are to be used. In the invention, tetanus toxoid is used as the carrier protein, even where multiple meningococcal conjugates are administered at the same time and where a patient has previously been exposed to the carrier protein, either in the form of a previous immunogen (e.g. in a DTP vaccine) or as a previous carrier protein (e.g. in a Hib or pneumococcal conjugate vaccine). The invention provides a method for immunising a patient, comprising administering multiple conjugates of meningococcal capsular saccharides, wherein each conjugate comprises a tetanus toxoid carrier protein, and the capsular saccharide, and wherein the patient has been pre-immunised with a tetanus toxoid. | 04-29-2010 |
20100119543 | USE OF SHIGELLA INVAPLEX TO TRANSPORT FUNCTIONAL PROTEINS AND TRANSCRIPTIONALLY ACTIVE NUCLEIC ACIDS ACROSS MAMMALIAN CELL MEMBRANES IN VITRO AND IN VIVO - The in vivo and in vitro use of Invaplex to transport materials, including functional proteins and biologically active nucleic acids, across eukaryotic cell membranes. The eukaryotic cells include a variety of cell types, e.g. insect, reptile, fish, mammal and tumor cells. The suitable materials for transport include biochemicals such as reporter molecules, antibiotics, biopharmaceuticals and carbohydrates including polysaccharides, lipopolysaccharides, polynucleotides, such as DNA and RNA, and glycoproteins and proteins including antigens, enzymes, antibodies, receptors and hormones. In addition, Invaplex enhances the immune response to DNA vaccines and also can function by itself as a vaccine against shigellosis. | 05-13-2010 |
20100119544 | VACCINE - The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from | 05-13-2010 |
20100136045 | NOVEL SHIGELLA PROTEIN ANTIGENS AND METHODS - The present invention relates to protein antigens IcsP2 and SigA2 from | 06-03-2010 |
20100143399 | PROCESS FOR MANUFACTURING VACCINES - The present application discloses a method for making an immunogenic composition comprising an improved way of conducting saccharide-protein conjugation reactions using carbodiimide condensation chemistry. Depending on the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. In addition, the conjugate is mixed with a staphylococcal antigen. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed. | 06-10-2010 |
20100143400 | Immunostimulatory Oligonucleotides - The invention relates to immunostimulatory oligonucleotides and methods of using immunostimulatory oligonucleotides to induce an antigen-specific immune response. The invention further relates to a vaccine that comprises an immunostimulatory oligonucleotide and an antigen, and comprises a pharmaceutically acceptable carrier. The immunostimulatory oligonucleotides of the invention, in some embodiments, include one or more modified linkage(s). | 06-10-2010 |
20100150956 | MULTICOMPONENT VACCINES - Multicomponent vaccines are provided which aid in the prevention and treatment of staphylococcal infections and which include certain selected combinations of bacterial binding proteins or fragments thereof, or antibodies to those proteins or fragments. By careful selection of the proteins, fragments, or antibodies, a vaccine is provided that imparts protection against a broad spectrum of | 06-17-2010 |
20100172931 | Pharmaceutical Composition Containing the NMB1796 Protein - The present invention is related to field of medicine, particularly to the development of pharmaceutical composition containing the NMB1796 protein. The composition described in this invention are able to confer protection against different diseases caused or not by pathogenic agents. The NMB1796 protein was identified as a | 07-08-2010 |
20100183662 | VACCINE COMPRISING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CONJUGATES - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition is provided comprising a multivalent | 07-22-2010 |
20100189740 | MODIFIED POLYSACCHARIDES FOR CONJUGATE VACCINES - The present invention relates to methods of manufacture of immunogenic glycoconjugates, in particular for use in pharmaceutical compositions for inducing a therapeutic immune response in a subject. The immunogenic glycoconjugates of the invention comprise one or more oligosaccharides or polysaccharides that are conjugated to one or more carrier proteins via an active aldehyde group. Accordingly, the invention provides methods of making (i) unsaturated microbial N-acyl derivative oligosaccharides or polysaccharides; (ii) novel conjugates of unsaturated N-acyl derivatives; and (iii) glycoconjugate compositions comprising conjugate molecules of fragments of microbial unsaturated N-acyl derivatives that serve as a covalent linker to one or more proteins. The invention further encompasses the use of the immunogenic glycoconjugates pharmaceutical compositions for the prevention or treatment of an infectious disease. | 07-29-2010 |
20100196416 | Vaccine - A typhoid vaccine using heat shock protein (Hsp) of | 08-05-2010 |
20100196417 | COMPOSITIONS COMPRISING A B SUBUNIT OF SHIGA TOXIN AND A MEANS STIMULATING NKT CELLS - The present invention relates to a composition comprising a) a B subunit of Shiga toxin or a functional equivalent thereof which is able to bind the Gb3 receptor, complexed with an antigen and b) at least one ligand of CDI capable of stimulating NK T cells; and to a pharmaceutical composition and a medicament comprising said composition. | 08-05-2010 |
20100196418 | UNIVERSAL CARRIER FOR TARGETING MOLECULES TO Gb3 RECEPTOR EXPRESSING CELLS - The present invention concerns an universal polypeptidic carrier for targeting directly or indirectly a molecule to Gb3 receptor expressing cells and having the following formula STxB-Z(n)-Cys, wherein:
| 08-05-2010 |
20100209450 | VACCINE COMPRISING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CONJUGATES - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent | 08-19-2010 |
20100233201 | VACCINE COMPOSITION - The present invention relates to the field of vaccines, and in particular vaccines comprising antigens of low isoelectric point at pH 7.0, in particular the capsular polysaccharide or oligosaccharide of | 09-16-2010 |
20100239604 | VACCINE COMPRISING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CONJUGATES - The present invention relates to an immunogenic composition comprising | 09-23-2010 |
20100255026 | Methods and compositions relating to anthrax spore glycoproteins as vaccines - Disclosed are methods for preparing an anthrax spore glycoprotein complex vaccine. Also, disclosed compositions of an anthrax vaccine including a spore glycoprotein complex as the active agent. In certain embodiments, the vaccines are sufficient to protect against infection from | 10-07-2010 |
20100266625 | Meningococcal and Pneumococcal Conjugate Vaccine and Method of Using Same - This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both | 10-21-2010 |
20100266626 | ADJUVANTED GLUCANS - The use of beta-glucans as antigens for immunising against fungi is known. According to the invention, the beta-glucans are administered together with an adjuvant. The adjuvant improves the immune response. The glucan will usually be conjugated to a carrier. Suitable glucans include laminarin and curdlan. | 10-21-2010 |
20100278856 | BoNT/A PEPTIDES AND METHODSOF PREDICTING AND REDUCING IMMUNORESISTANCE TO BOTULINUM TOXIN THERAPY - The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides. | 11-04-2010 |
20100291136 | Pharmaceutical Liquid Composition of Botulinum Toxin With Improved Stability - Disclosed herein is a liquid pharmaceutical composition of | 11-18-2010 |
20100291137 | METHOD FOR REFOLDING NEISSERIAL NSPA PROTEIN - The present invention provides an isolated refolded NspA protein, and a method of preparing it. | 11-18-2010 |
20100291138 | Vaccine - The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to vaccines comprising a pneumococcal polysaccharide antigen, typically a pneumococcal polysaccharide conjugate antigen, formulated with a protein antigen form | 11-18-2010 |
20100297166 | Meningococcal Oligosaccharide Linked Polysaccharides and Diptheria Protein Conjucate Vaccine for All Ages - Methods for producing quadrivalent meningococcal meningitis polysaccharide and conjugate vaccines for serotypes A, C, Y and W-135 disclosed. | 11-25-2010 |
20100316666 | Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition - An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of | 12-16-2010 |
20110008385 | Immunogenic composition - The present application relates to immunogenic compositions comprising staphylococcal PNAG and Type 5 and/or 8 capular polysaccharide or oligosaccharide from | 01-13-2011 |
20110020390 | MENINGOCOCCAL FHBP POLYPEPTIDES - fHBP is a protein in | 01-27-2011 |
20110027307 | ANTI-SEPSIS CONJUGATE VACCINE - The present invention provides an immunogenic conjugate comprising biologically deacylated gram-negative bacterial moieties linked to | 02-03-2011 |
20110033494 | Anti-Infective Agents and Uses Thereof - The present invention is concerned with novel immunostimulant microparticle compositions and their use as anti-infective agents in the treatment of bacterial and viral infections. | 02-10-2011 |
20110045015 | CONJUGATED BETA-1,3-LINKED GLUCANS - Glucans having exclusively or mainly β-1,3 linkages are used as immunogens. These comprise β-1,3-linked glucose residues. Optionally, they may include β-1,6-linked glucose residues, provided that the ratio of β-1,3-linked residues to β-1,6-linked residues is at least 8:1 and/or there are one or more sequences of at least five adjacent non-terminal residues linked to other residues only by β-1,3 linkages. The glucans will usually be used in conjugated form. A preferred glucan source is curdlan, which may be hydrolysed to a suitable form prior to conjugation. | 02-24-2011 |
20110052624 | Type 5 And Type 8 Capsular Polysaccharides Of Overproducing S. Aureus Strains - The invention relates to the type 5 and type 8 capsular polysaccharides produced by overproducing | 03-03-2011 |
20110059125 | ZWITTERIONIC IMMUNOMODULATORS FOR THE TREATMENT OF ASTHMA AND ALLERGY - Methods and products for treating and protecting against asthma and allergic conditions are provided. The methods and products are related to certain naturally occurring and synthetic zwitterionic polymers which are found to induce certain T regulatory (Treg) cells and to exert immunosuppressive effects in vitro and in vivo. | 03-10-2011 |
20110070259 | Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine - The present invention describes derivatized polysaccharide-protein conjugates, a composition comprising one or more of such derivatized polysaccharide-protein conjugates and methods of immunizing human patients with the same. The derivatized polysaccharide-protein conjugates are purified capsular polysaccharides from | 03-24-2011 |
20110097357 | BIOCONJUGATES MADE FROM RECOMBINANT N-GLYCOSYLATED PROTEINS FROM PROCARYOTIC CELLS - The present invention is directed to a bioconjugate vaccine, such as an 01-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X—N—Z—S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps. | 04-28-2011 |
20110117123 | Multivalent Vaccine Composition With Mixed Carrier - The invention concerns a pharmaceutical composition for treating or preventing a certain number of infections caused by pathogenic agents such as bacteria, comprising as immunogen, one or several polyosides derived from one or several pathogenic agents. The polyosides are in the form of conjugates, coupled with a carrier protein. The composition contains at least two types of conjugates, each being at least characterised by a different protein carrier. | 05-19-2011 |
20110142876 | CONJUGATED VI SACCHARIDES - Two Vi conjugates have been prepared by carbodiimide-mediated synthesis, using adipic acid dihydrazide derivatized CRM | 06-16-2011 |
20110150923 | MUCOSAL MENINGOCOCCAL VACCINES - The invention provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of | 06-23-2011 |
20110159029 | MEASURING DEGREE OF POLYMERISATION FOR MENINGOCOCCAL CAPSULAR SACCHARIDES THAT CONTAIN SIALIC ACID - The degree of polymerisation (DP) is an important parameter for analysis of saccharide antigens, particularly in glycoconjugates. The invention provides methods that can be used to measure DP for capsular saccharides, particularly for meningococcal saccharides e.g. from serogroups W135 and Y. A preferred method is based on reduction of terminal sialic acid residues on saccharides, with DP then being calculated by comparing the molar ratio of total sialic acid to reduced sialic acid. | 06-30-2011 |
20110159030 | MUCOSAL COMBINATION VACCINES FOR BACTERIAL MENINGITIS - A composition for mucosal delivery, comprising two or more of the following: (a) an antigen which induces an immune response against | 06-30-2011 |
20110189223 | VACCINE - The present invention provides an immunogenic composition comprising an antigen or antigen composition and an adjuvant composition comprising an oil in water emulsion. | 08-04-2011 |
20110195086 | 15-VALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE VACCINE COMPOSITION - The present invention provides a multivalent immunogenic composition having 15 distinct polysaccharide-protein conjugates. Each conjugate consists of a capsular polysaccharide prepared from a different serotype of | 08-11-2011 |
20110206726 | COMBINATION VACCINE WITH ACELLULAR PERTUSSIS - The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, acellular pertussis, and infections caused by | 08-25-2011 |
20110212125 | VACCINE FOR SHIGELLA - Disclosed are immunogenic conjugates and therapeutic compositions that include such immunogenic conjugates. Also disclosed are methods of treating and/or inhibiting an | 09-01-2011 |
20110229513 | LPS Based Vaccines - The removal of the glycosidic phosphate from the reducing end of the derived LPS molecule creates an aldehydo functionality which causes the formation of an immunologically dominant neo-epitope. Conjugation to the reducing end of a carbohydrate molecule following removal of the glycosidic phosphate traps the reducing glucosamine residue in an open-chain form which surprisingly was found to dominate the immune response. We therefore modified our conjugation strategy to avoid this open-chain form, by utilising the amino functionality created by the isolated amidase activity from | 09-22-2011 |
20110236414 | Bacterial Polysaccharide-Polypeptide Conjugate Compositions - The present invention relates to improved bacterial polysaccharide-polypeptide conjugate compositions, pharmaceutical compositions comprising such bacterial polysaccharide-polypeptide conjugate compositions, and the use of such compositions. Furthermore, the invention relates to the use of a combination of a peptide of the formula R | 09-29-2011 |
20110256172 | EPITOPE-TARGETED ANTHRAX VACCINE - Anthrax vaccine compositions comprise a segment of a PA toxin protein that stimulates a B cell immune response specific for a defined epitope on the protective antigen of | 10-20-2011 |
20110256173 | CHEMICAL SYNTHESIS OF PHOSPHATIDYLINOSITOL MANNOSIDE GLYCANS FROM MYCOBACTERIUM TUBERCULOSIS - The efficient synthesis of phosphatidylinositol mono- to hexa-mannoside (PIM | 10-20-2011 |
20110274717 | POLYSACCHARIDE CONJUGATION WITH DETOXIFIED E. coli HEAT LABILE ENTEROTOXIN (LT) USED AS VACCINE - A detoxified recombinant | 11-10-2011 |
20110287049 | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES - Active immunotherapy methods for treating a human patient having an amyloid disease characterized by the presence of amyloid fibrils comprising islet amyloid polypeptide (IAPP). | 11-24-2011 |
20110311575 | MIXING LYOPHILISED MENINGOCOCCAL VACCINES WITH D-T-Pa VACCINES - A liquid D-T-Pa component is used to reconstitute a lyophilised meningococcal component, thereby producing a combined vaccine. | 12-22-2011 |
20110311576 | MIXING LYOPHILISED MENINGOCOCCAL VACCINES WITH NON-HIB VACCINES - An aqueous immunogen formulation is used to reconstitute a lyophilised component including conjugates of capsular saccharides from | 12-22-2011 |
20110311577 | METHOD OF PRODUCING A VACCINE - The present invention relates to a method for purifying bacterial cytolysins such as pneumococcal pneumolysin. A single chromatography step produces excellent purification of the cytolysin by binding soluble aggregated cytolysin to a hydrophobic interaction chromatography material in the presence of detergent and high salt. | 12-22-2011 |
20120009213 | Meningococcal And Pneumococcal Conjugate Vaccine And Method Of Using Same - This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both | 01-12-2012 |
20120034261 | NOVEL IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE - The present invention relates to | 02-09-2012 |
20120107346 | COMBINATION VACCINES WITH LOW DOES OF HIB CONJUGATE - Provided herein are combination vaccines comprising antigens for protecting a subject against at least diphtheria, tetanus, pertussis and Hib, wherein: (a) the antigen for protecting against Hib is a conjugate of a Hib capsular saccharide; (b) the concentration of the Hib conjugate in the vaccine is <15 μg/ml; and (c) the Hib conjugate has never been lyophilised. | 05-03-2012 |
20120128712 | VACCINE DIRECTED AGAINST PORCINE PLEUROPNEUMONIA AND A METHOD TO OBTAIN SUCH A VACCINE - The present invention pertains to a vaccine directed against porcine pleuropneumonia, comprising lipopolysaccharide, wherein the vaccine comprises a polymyxin to reduce symptoms of an endotoxic shock arising from the lipopolysaccharide. The invention also pertains to a method to obtain such a vaccine and a method for administering the vaccine to a subject animal. | 05-24-2012 |
20120135030 | Method of Producing Protein-Carbohydrate Vaccines Reduced in Free Carbohydrate - This invention is directed to processes for reducing the level of free carbohydrate from a solution of protein-linked carbohydrate (conjugate) and non-linked carbohydrate. In this process, the conjugate is adsorbed to a hydrophobic membrane while the carbohydrate is not. The conjugate is then desorbed from the membrane, yielding a solution that is substantially reduced in free carbohydrate. | 05-31-2012 |
20120171241 | ANALYSIS OF SACCHARIDE VACCINES WITHOUT INTERFERENCE - The invention is based on methods that allow analysis of mixed meningococcal saccharides from multiple serogroups even though they share monosaccharide units. With a combination of saccharides from serogroups C, W135 and Y, the invention analyses sialic acid, glucose and galactose content. The glucose and galactose results are used to directly quantify saccharides from serogroups Y and W135, respectively, and the combined glucose and galactose content is subtracted from the sialic acid content to quantify saccharides from serogroup C. The three serogroups can thus be resolved even though their monosaccharide contents overlap. The three different monosaccharide analyses can be performed on the same material, without interference between the monosaccharides and without interference from any other saccharide materials in the composition (e.g. lyophilisation stabilisers). The method can be used to analyse total and free saccharide in conjugate vaccines and simplifies quality control of vaccines containing capsular saccharides from multiple serogroups. | 07-05-2012 |
20120189654 | VACCINE - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent | 07-26-2012 |
20120207781 | DIMENSIONAL ANALYSIS OF SACCHARIDE CONJUGATES WITH GPC & SEC MALS - GPC (gel permeation chromatography) and size exclusion chromatography with detection by multi-angle light-scattering photometry (SEC-MALS) can be used to accurately measure molecular size and molar mass, respectively, of saccharide conjugates. The invention provides (a) a process for measuring the molecular size of a conjugated saccharide antigen within a sample, comprising a step of analysing the sample by GPC, and (b) a process for measuring the molar mass of a conjugated saccharide antigen within a sample, comprising a step of analysing the sample by SEC-MALS. | 08-16-2012 |
20120237542 | MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION - An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of | 09-20-2012 |
20120258132 | Vagal Nerve-Based Disorders - The present specification discloses TEMs, compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, methods of treating a vagal nerve-based disorder in an individual using such compositions, use of such TEMs in manufacturing a medicament for treating a vagal nerve-based disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating a vagal nerve-based disorder, use of such TEMs in treating a vagal nerve-based disorder, and use of such TEMs and Clostridial toxins in treating a vagal nerve-based disorder. | 10-11-2012 |
20120276137 | COMPOSITIONS AND METHODS FOR PREPARING STAPHYLOCOCCUS AUREUS SEROTYPE 5 AND 8 CAPSULAR POLYSACCHARIDE CONJUGATE IMMUNOGENIC COMPOSITIONS - The present invention relates to immunogenic conjugates comprising | 11-01-2012 |
20120301500 | ANTI-SEPSIS CONJUGATE VACCINE - The present invention provides an immunogenic conjugate comprising biologically deacylated gram-negative bacterial moieties linked to | 11-29-2012 |
20120301501 | METHOD FOR SELECTING AND PRODUCING VACCINE COMPONENTS AND VACCINES BASED THEREON - The invention relates to the field of biology, more specifically to the field of immunology and microbiology. The invention further relates to the field of vaccines against microbial infections and especially bacterial vaccines, in particular to pneumococcal vaccines. More in particular, the invention relates to means and methods to identify, select and isolate a vaccine component for passive and/or active immunisation against a microorganism that can be killed by opsonophagocytic cells. The invention relates to a method to identify an opsonophagocytosis inducing antigen as a vaccine component for immunisation against a microorganism. The invention describes three pneumococcal proteins SlrA, IgA1 proteinase, and PsaA, and their use as a vaccine component with or without PpmA. The invention also discloses the use of antibodies against said proteins for passive immunization and diagnosis. | 11-29-2012 |
20120301502 | 15-VALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE VACCINE COMPOSITION - The present invention provides a multivalent immunogenic composition having 15 distinct polysaccharide-protein conjugates. Each conjugate consists of a capsular polysaccharide prepared from a different serotype of | 11-29-2012 |
20120321660 | CONJUGATION PROCESS OF BACTERIAL POLYSACCHARIDES TO CARRIER PROTEINS - Process for conjugation of bacterial saccharides including | 12-20-2012 |
20130004535 | MULTIPLE VACCINATION INCLUDING SEROGROUP C MENINGOCOCCUS - Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular | 01-03-2013 |
20130004536 | MULTIPLE VACCINATION INCLUDING SEROGROUP C MENINGOCOCCUS - Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular | 01-03-2013 |
20130034579 | IMMUNOGENIC COMPOSITIONS AND RELATED METHODS - This disclosure relates to adjuvants for use in immunogenic compositions comprising at least one antigen and an aluminum compound comprising hydroxyl groups that has been treated with phosphate, carboxylate, carbonate, sulfate diphosphonate or a mixture of two or more of these compounds and methods of using these compositions for preventing and treating diseases are also provided. | 02-07-2013 |
20130034580 | NOVEL FORMULATIONS WHICH STABILIZE AND INHIBIT PRECIPITATION OF IMMUNOGENIC COMPOSITIONS - The present invention addresses an ongoing need in the art to improve the stability of immunogenic compositions such as polysaccharide-protein conjugates and protein immunogens. The invention broadly relates to novel formulations which stabilize and inhibit precipitation of immunogenic compositions. More particularly, the invention described hereinafter, addresses a need in the art for formulations which stabilize and inhibit particulate formation (e.g., aggregation, precipitation) of immunogenic compositions which are processed, developed, formulated, manufactured and/or stored in container means such as fermentors, bioreactors, vials, flasks, bags, syringes, rubber stoppers, tubing and the like. | 02-07-2013 |
20130071428 | PEPTIDES, CONJUGATES AND METHOD FOR INCREASING IMMUNOGENICITY OF A VACCINE - The present invention relates to conjugates comprising a peptide of at least 10 amino acid residues comprising the amino acid sequence GITELKKL for induction of potent humoral and cellular immune responses when administered to subjects having antibodies against tetanus toxoid. In one embodiment the invention relates to a prophylactic and therapeutic vaccine and in a further embodiment the invention relates to the treatment or prevention of cancer or an infectious disease. | 03-21-2013 |
20130078273 | Vault Compositions For Immunization - Methods and compositions are provided herein for immunizing a subject by administering to the subject an effective amount of an immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity. | 03-28-2013 |
20130122037 | Vault Compositions for Immunization - Methods and compositions are provided herein for immunizing a subject by administering to the subject an effective amount of an immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity. | 05-16-2013 |
20130129776 | Broad Spectrum Vaccine Against Typhoidal and Non-typhoidal Salmonella Disease - The present invention is drawn to multivalent | 05-23-2013 |
20130129777 | CONJUGATES OF PLASMODIUM FALCIPARUM SURFACE PROTEINS AS MALARIA VACCINES - Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against | 05-23-2013 |
20130142822 | CONJUGATED VI SACCHARIDES - Two Vi conjugates have been prepared by carbodiimide-mediated synthesis, using adipic acid dihydrazide derivatized CRM | 06-06-2013 |
20130164325 | CERAMIDE-LIKE GLYCOLIPID-ASSOCIATED BACTERIAL VACCINES AND USES THEREOF - The invention is directed compositions and methods related to bacterial cells that are physically associated with ceramide-like glycolipids for use as antigen carriers for heterologous antigens. The invention further relates to methods of incorporating ceramide-like glycolipid to bacterial cell walls. The compositions and methods of the present invention are useful for the prevention and treatment of diseases. | 06-27-2013 |
20130171187 | GLUCAN-BASED VACCINES - Anti-glucan antibodies have been found to be protective against systemic fungal infection with | 07-04-2013 |
20130171188 | IMMUNOGENIC COMPOSITION - The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example | 07-04-2013 |
20130177588 | Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine - The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria | 07-11-2013 |
20130189300 | CARRIER MOLECULE - The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a spr0096 antigen and a spr2021 antigen. spr0096 and spr2021 are | 07-25-2013 |
20130216571 | Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine - The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria | 08-22-2013 |
20130224241 | Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine - The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria | 08-29-2013 |
20130251745 | VACCINE - The present invention relates to the field of vaccines and in particular to combination vaccines and co-administration schedules. The present inventors disclose that overuse of CRM in paediatric vaccines can result in bystander immune interference to certain antigens and provide solutions to this problem. | 09-26-2013 |
20130259896 | Stable Immunogenic Compositions of Staphylococcus Aureus Antigens - The present invention is directed towards a lyophilized or reconstituted multi-antigen or multicomponent immunogenic composition comprising at least one antigen isolated from a staphylococcal bacterium, and methods of making the same. | 10-03-2013 |
20130266609 | VACCINE COMPOSITION - The present invention relates to DTP-based combination vaccine formulations, and concomitantly administered combination vaccine kits. Methods of administration of these vaccines and kits are also provided. | 10-10-2013 |
20130273097 | USE OF SACCHARIDES CROSS-REACTIVE WITH BACILLUS ANTHRACIS SPORE GLYCOPROTEIN AS A VACCINE AGAINST ANTHRAX - Provided are immunogenic compositions and methods for eliciting an immune response against | 10-17-2013 |
20130273098 | NOVEL FORMULATIONS WHICH MITIGATE AGITATION-INDUCED AGGREGATION OF IMMUNOGENIC COMPOSITIONS - The present invention provides novel formulations which mitigate agitation-induced aggregation of immunogenic compositions particularly those having polysaccharide-protein conjugates. Specifically, the novel formulations comprise a poloxamer within a molecular weight range of 1100 to 17,400 which provides significant advantages over previously used surfactants including polysorbate 80. In one embodiment, the present invention provides a multivalent immunogenic composition having 15 distinct polysaccharide-protein conjugates and a poloxamer. Each conjugate consists of a capsular polysaccharide prepared from a different serotype of | 10-17-2013 |
20130295132 | Conjugation of Streptococcal Capsular Saccharides - Three conjugation methods for use with the capsular saccharide of | 11-07-2013 |
20130337006 | POLYANIONIC POLYMER ADJUVANTS FOR HAEMOPHILUS INFLUENZAE B SACCHARIDE VACCINES - The present invention relates to immunogenic compositions comprising capsular polysaccharide or oligosaccharide of | 12-19-2013 |
20130344103 | CONJUGATION PROCESS - The present invention relates to a process for conjugation of an antigen. | 12-26-2013 |
20130344104 | OLIGOSACCHARIDES AND OLIGOSACCHARIDE-PROTEIN CONJUGATES DERIVED FROM CLOSTRIDIUM DIFFICILE POLYSACCHARIDE PS-II, METHODS OF SYNTHESIS AND USES THEREOF, IN PARTICULAR AS A VACCINE - The present invention provides an oligosaccharide-protein conjugate comprising an oligosaccharide, in particular synthetic oligosaccharide, derived from the repeating unit of the | 12-26-2013 |
20140065183 | CONJUGATES OF ACYL HOMOSERINE LACTONE AND CATALASE A FROM PSEUDOMONAS AERUGINOSA - The present invention is directed to an acyl homoserine lactone and catalase conjugate wherein the acyl homoserine lactone is N-3-(oxododecanoyl)-L-homoserine lactone (OdDHL) or butyryl L-homoserine lactone (BHL) and the catalase is a | 03-06-2014 |
20140099337 | Pneumococcal Vaccine and Uses Thereof - The present invention relates to new pneumococcal vaccines. The invention also relates to vaccination of subjects, in particular immunocompromised subjects, against pneumoccocal infections using said novel pneumococcal vaccines. | 04-10-2014 |
20140186388 | Method for Producing Protein-Carbohydrate Vaccines Reduced in Free Carbohydrate - This invention is directed to processes for reducing the level of free carbohydrate from a solution of protein-linked carbohydrate (conjugate) and non-linked carbohydrate. In this process, the conjugate is adsorbed to a hydrophobic membrane while the carbohydrate is not. The conjugate is then desorbed from the membrane, yielding a solution that is substantially reduced in free carbohydrate. | 07-03-2014 |
20140186389 | CONJUGATION PROCESS OF BACTERIAL POLYSACCHARIDES TO CARRIER PROTEINS - Process for conjugation of bacterial saccharides including | 07-03-2014 |
20140186390 | CONJUGATION PROCESS OF BACTERIAL POLYSACCHARIDES TO CARRIER PROTEINS - Process for conjugation of bacterial saccharides including | 07-03-2014 |
20140205630 | COMPOSITIONS COMPRISING A B SUBUNIT OF SHIGA TOXIN AND A MEANS STIMULATING NKT CELLS - The present invention relates to a composition comprising a) a B subunit of Shiga toxin or a functional equivalent thereof which is able to bind the Gb3 receptor, complexed with an antigen and b) at least one ligand of CDl capable of stimulating NK T cells; and to a pharmaceutical composition and a medicament comprising said composition. | 07-24-2014 |
20140234368 | HYPO- AND HYPER-ACETYLATED MENINGOCOCCAL CAPSULAR SACCHARIDES - Capsular saccharides derived from serogroups W135 and Y of | 08-21-2014 |
20140242110 | Dose, localization, and formulation of botulinum toxins in skin and muscle - Formulations of and dosing protocols for the administration of botulinum toxin that maximize efficacy and specificity while minimizing the likelihood of overdosing and undesirable side effects of treatment. The formulations include positively charged carriers, such as cationic peptides, which otherwise have no inherent botulinum-toxin-like activity. The dosing regimen is based on the pattern, quantity, and location of neuromuscular junctions in the target tissue. Because the number of neuromuscular junctions in a target tissue remains generally stable throughout life and because the pharmacological effect of botulinum toxin is localized at the neuromuscular junction, dosing efficacy is unaffected by muscle mass, age of the patient, or body weight. | 08-28-2014 |
20140302087 | MANUFACTURE OF VACCINES THAT CONTAIN BOTH HEPATITIS B VIRUS SURFACE ANTIGEN AND SURFACTANT - When preparing HBsAg for use in a combination vaccine, it is known to add a non-ionic detergent after the HBsAg has been purified. Adding detergents after purification of HBsAg is not optimal, however, as it requires a separate processing step during manufacture. Thus the invention uses them during HBsAg purification. | 10-09-2014 |
20140308311 | Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine - The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria | 10-16-2014 |
20140314805 | MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION - An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of | 10-23-2014 |
20140322263 | PNEUMOCOCCAL DOSING REGIMEN - Methods of immunizing older adult subjects against | 10-30-2014 |
20140341945 | DELAMINATION RESISTANT PHARMACEUTICAL GLASS CONTAINERS CONTAINING ACTIVE PHARMACEUTICAL INGREDIENTS - The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine). | 11-20-2014 |
20140363463 | SHORTENED PURIFICATION PROCESS FOR THE PRODUCTION OF CAPSULAR STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDES - A shortened process for producing a solution containing substantially purified capsular polysaccharides from a cellular | 12-11-2014 |
20150010592 | CAPSULAR GRAM-POSITIVE BACTERIA BIOCONJUGATE VACCINES - The present invention encompasses a novel | 01-08-2015 |
20150037368 | POLYANIONIC POLYMER ADJUVANTS FOR HAEMOPHILUS INFLUENZAE B SACCHARIDE VACCINES - The present invention relates to methods of reducing flocculation in an immunogenic composition, where said immunogenic composition comprises (a) | 02-05-2015 |
20150044254 | BIOCONJUGATES MADE FROM RECOMBINANT N-GLYCOSYLATED PROTEINS FROM PROCARYOTIC CELLS - The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps. | 02-12-2015 |
20150071961 | SIDEROPHORE CONJUGATE IMMUNOGENIC COMPOSITIONS AND VACCINES - An immunogenic composition comprising a siderophore covalently linked to a pharmaceutically acceptable carrier molecule wherein the antigenicity of the siderophore moiety is sufficient to stimulate an immunologic response to the siderophore when the composition is circulating in the bloodstream of a human or non-human animal and vaccine. | 03-12-2015 |
20150079129 | VACCINE - The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from | 03-19-2015 |
20150093411 | Chimeric Multivalent Polysaccharide Conjugate Vaccines - The present invention provides multivalent chimeric conjugate vaccine molecule and methods of using the conjugate to immunize subjects against bacterial infections. A conjugate molecule of the invention comprises multiple bacterial capsular polysaccharides linked to a carrier protein. Accordingly, the conjugate molecule provides immune protection against multiple types of bacteria in a single vaccines. In particular, conjugate molecules of the invention are used to prevent or attenuate Group B | 04-02-2015 |
20150093412 | USE OF SACCHARIDES CROSS-REACTIVE WITH BACILLUS ANTHRACIS SPORE GLYCOPROTEIN AS A VACCINE AGAINST ANTHRAX - Provided are immunogenic compositions and methods for eliciting an immune response against | 04-02-2015 |
20150104479 | MENINGOCOCCUS SEROGROUP X CONJUGATE - The invention provides a conjugate of a | 04-16-2015 |
20150118263 | GLYCOENGINEERED OUTER MEMBRANE VESICLES AND USE THEREOF AS VACCINES - The present application relates to glycoengineered outer membrane vesicles obtained from recombinant, gram-negaetive bacteria comprising hetereologous DNA encoding an enzyme or enzymes that produce a heterologous glycan that replaces all or a portion of the naturally-occurring O antigen in the lipopolysaccharides of the bacteria. Also provided by the present application are immunogenic compositions and vaccines prepared from the glycoengineered outer membrane vesicles expressing the heterologous glycans at their surface. | 04-30-2015 |
20150132339 | ADJUVANTED FORMULATIONS OF STREPTOCOCCUS PNEUMONIAE ANTIGENS - The efficacy of | 05-14-2015 |
20150290331 | GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI - The present invention relates to a conjugate comprising an oligo- or polysaccharide selected from the group consisting of: (X) | 10-15-2015 |
20150297750 | THERAPEUTIC AND VACCINE POLYELECTROLYTE NANOPARTICLE COMPOSITIONS - Polyelectrolyte nanoparticle compositions for biomedical applications are provided comprising at least two carrier domains comprising multivalent ionic domains and an agent exhibiting biological activity when contained within the nanoparticle or on the nanoparticle surface. The multivalent ionic domains may be contained in two separate molecules or in separate but linked domains of a single molecule. The nanoparticle optionally can further comprise an exposed targeting ligand and/or protective surface. The nanoparticle can be contacted to cells or administered directly to an animal for biomedical applications including therapeutics and immune response. The nanoparticle may alternatively be comprised of a carrier material capable of delivering various medically important antigens as vaccine. | 10-22-2015 |
20150299750 | PRODUCTION OF HIGH YIELDS OF BACTERIAL POLYSACCHARIDES - The instant invention provides improved culture, fermentation and purification conditions for preparing | 10-22-2015 |
20150306214 | ADJUVANT FOR MUCOSAL VACCINE - An object of the present invention is to provide an adjuvant for a mucosal vaccine with high safety that induces a sufficient immune response on the mucosa. According to the present invention, an adjuvant for a mucosal vaccine comprising a protein complex composed of hemagglutinin (HA) subcomponents HA1, HA2, and HA3 of botulinum toxin is provided. | 10-29-2015 |
20150315225 | PURIFICATION OF STAPHYLOCOCCUS AUREUS TYPE 8 CAPSULAR SACCHARIDES - The invention provides a method for releasing capsular polysaccharide from | 11-05-2015 |
20150320852 | CONJUGATES FOR PROTECTING AGAINST DIPHTHERIA AND/OR TETANUS - Saccharide conjugate vaccines which use diphtheria toxoid or tetanus toxoid as a carrier protein can confer protection against lethal challenge by diphtheria toxin or tetanus toxin. Thus, in addition to protecting against the bacteria whose saccharides have been attached to the carrier, such conjugate vaccines can also be used to protect against diphtheria and tetanus, so the diphtheria toxoid and tetanus toxoid components of current complex combination vaccines may be superfluous. Therefore the antigenic complexity of these vaccines can be reduced without reducing their breadth of protection, and removing these superfluous components creates space in the vaccine for adding immunogens for protecting against further pathogens. The same effect is not seen with a CRM197 carrier, but this observation makes this carrier more attractive for conjugate vaccines which are given concomitantly with infant combination vaccines that contain Dt and Tt. | 11-12-2015 |
20150328328 | GLYCOCONJUGATION PROCESS - The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions. | 11-19-2015 |
20150343076 | MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION - Provided is an immunogenic composition comprising 13 different polysaccharide-protein conjugates. Each of the conjugates comprises a capsular polysaccharide prepared from a different serotype Streptococcus pneumoniae conjugated to a carrier protein, that is, 12 serotypes selected from the group consisting of 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F and serotype 22F or 33F. The immunogenic composition formulated into a vaccine comprising an aluminum-based adjuvant increases coverage with respect to pneumococcal diseases in infants and children. | 12-03-2015 |
20150352216 | CONJUGATE OF A FRAGMENT OF A CELLULAR WALL OF A BACTERIUM AND A MUCOPOLYSACCHARIDIC CARRIER, AND USES IN MEDICINE THEREOF - The present invention relates in one aspect to a conjugate of a mucopolysaccharide or mucopolysaccharidic fraction and a cellular wall fragment of a bacterium belonging to the | 12-10-2015 |
20160000928 | Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine - The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria | 01-07-2016 |
20160022798 | COMPOSITIONS AND METHODS FOR PREPARING STAPHYLOCOCCUS AUREUS SEROTYPE 5 AND 8 CAPSULAR POLYSACCHARIDE CONJUGATE IMMUNOGENIC COMPOSITIONS - The present invention relates to immunogenic conjugates comprising | 01-28-2016 |
20160067325 | Purification of Polysaccharide Protein Conjugates - The invention describes a method of purifying polysaccharide protein conjugates using mixed mode chromatography. The method involves contacting a crude polysaccharide protein conjugate with a mixed mode resin comprising an inert porous shell and an activated core under conditions of low conductivity that allow binding of the contaminants and collecting the unbound polysaccharide protein conjugate in a flowthrough. | 03-10-2016 |
20160120967 | MODIFIED ENDOTOXIC BACTERIA LIPOPOLYSACCHARIDE (VARIANTS), COMBINATION OF MODIFIED LIPOPOLYSACCHARIDES (VARIANTS) AND, CONTAINING SAME, A VACCINE (VARIANTS) AND A PHARMACEUTICAL COMPOSITION (VARIANTS) - For the first time individual (free from impurities of penta- and hexa-acetylated derivatives) di-, tri- and tetra-acetylated S-LPS of endotoxic bacteria and combinations thereof were obtained and their immunobiological, physical-chemical and chemical-pharmaceutical properties were studied. | 05-05-2016 |
20160136257 | PROTEIN MATRIX VACCINES AND RELATED METHODS OF MAKING AND ADMINISTERING SUCH VACCINES - The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration. | 05-19-2016 |
20160375131 | METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF - Provided herein are methods for rational design of nicotine haptens. More particularly, provided herein are methods for designing, selecting, and synthesizing nicotine haptens and nicotine hapten conjugates. Also provided herein are novel nicotine haptens and methods for using nicotine haptens to treat nicotine addiction. | 12-29-2016 |
20160376301 | PURIFICATION OF STAPHYLOCOCCUS AUREUS TYPE 5 AND TYPE 8 CAPSULAR SACCHARIDES - The invention provides a method for releasing capsular polysaccharide from | 12-29-2016 |
20170232093 | MODIFIED HOST CELLS AND HYBRID OLIGOSACCHARIDES FOR USE IN BIOCONJUGATE PRODUCTION | 08-17-2017 |